Diagnosing aplastic anemia: essential tests and targeted investigations

Finding low red cells, white cells, and platelets does not by itself confirm aplastic anemia. The diagnostic workup asks why the cells are low, whether production has genuinely failed, and whether a different disorder would require another treatment pathway. These questions are answered by a hematologist combining several forms of evidence. There is no single positive aplastic-anemia marker that can perform the whole task.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

A complete blood count should be reviewed with the differential, especially the absolute neutrophil count. A total white-cell number that seems only modestly reduced can hide important neutropenia. Reticulocytes are recently produced red cells; interpreting their absolute number alongside the anemia helps assess the marrow’s response. A blood film adds information about cell appearance and possible abnormal circulating cells.
PNH testing identifies populations of cells that lack particular protective surface proteins. These populations can coexist with aplastic anemia and provide both diagnostic context and a baseline for follow-up. The report should identify the cell populations examined, clone measurements, and assay sensitivity. Previous transfusions can affect interpretation of some findings.
For a diagnostic review in China, send serial counts, reticulocytes, complete aspirate and biopsy reports, original karyotype wording, PNH findings, and a medication/transfusion timeline. Ask whether slides, blocks, or other original material are required and how the hospital receives them. Translation should preserve units, specimen type, and qualifiers such as uncertain or unable to analyze. A phone image containing only the conclusion page is often insufficient.

Quick answer

Full guide

Fever, significant bleeding, or breathlessness should be assessed promptly at a service able to provide emergency and hematology care. Collecting diagnostic specimens can be coordinated with protecting the patient. Necessary treatment does not have to wait for every external report. The sequence below explains the reasoning; an individual’s tests will depend on age, symptoms, and work already completed. NHLBI: Aplastic anemia

Establish the pattern of low counts

A complete blood count should be reviewed with the differential, especially the absolute neutrophil count. A total white-cell number that seems only modestly reduced can hide important neutropenia. Reticulocytes are recently produced red cells; interpreting their absolute number alongside the anemia helps assess the marrow’s response. A blood film adds information about cell appearance and possible abnormal circulating cells.

Repeat testing can establish whether the problem persists. Specimen issues, recent infection, and medications may affect results. Previous routine blood counts and pretransfusion measurements are therefore valuable. Tell the clinician when fatigue, bruising, or gum bleeding began and whether earlier records showed longstanding mild thrombocytopenia. The timeline can alter the interpretation of the cause, not merely establish how long the patient has felt unwell.

Do not refuse a necessary transfusion just to preserve an untreated measurement. Clinicians can collect samples beforehand when practical, but safety takes priority. Recording the date and type of transfusion helps interpret later values. Previous transfusion records can also contain antibody or compatibility information needed for subsequent support. Schrezenmeier et al.: Transfusion Support, EBMT Handbook 2024

Why aspiration and a core biopsy often go together

Aspiration provides liquid marrow for examining individual cells and for selected flow-cytometry or genetic studies. A core biopsy shows overall cellularity and tissue architecture. Aplastic anemia commonly has reduced blood-forming tissue with a relative increase in fat, but marrow distribution can be uneven, making specimen adequacy important.

The procedures provide complementary information. A low-cellularity description from one sample does not automatically make the other investigation unnecessary. Before sampling, the service should identify which material is needed for morphology, histology, flow cytometry, chromosomes, and any additional studies. Platelet deficiency, coagulation abnormalities, and local infection may influence procedural preparation and support. Patients can also ask about pain relief before the appointment.

A scant aspirate is not automatically diagnostic of aplastic anemia. Fibrosis and other marrow conditions can make aspiration difficult. If the sample is markedly diluted or inadequate, the report should describe the resulting limitations. A repeat sample should address an identified unresolved question. When expert review of the original material can answer that question, repeating a procedure is not a substitute for specialist interpretation. BSH 2024 adult aplastic anaemia guideline

Exclude disorders that can resemble aplastic anemia

Hypocellular myelodysplastic neoplasia is an important alternative. Review may examine abnormal granulocyte or megakaryocyte development, increased blasts, and chromosome or molecular findings that support a different diagnosis. Limited erythroid changes or one somatic mutation should not be treated as a complete diagnosis in isolation. The clinical history, morphology, biopsy, and genetics need to fit together.

Nutritional deficiencies, infections, immune disorders, medicines, and toxic exposures are assessed according to the clinical clues. Provide every prescription, recent antibiotic, supplement, and relevant workplace exposure with its timing. A reported chemical exposure does not prove causation, and no obvious exposure does not exclude acquired aplastic anemia. In some patients, no single initiating event can be established despite a careful investigation.

Imaging is usually directed at a particular concern, such as splenic enlargement or liver disease, rather than a mandatory whole-body cancer-scan package. Before an expensive test, ask what diagnosis it could exclude, whether the answer would change care, and whether existing material can answer the same question. This is a way to clarify the investigation, not to avoid a test that has a clear indication. Peffault de Latour et al.: Acquired Bone Marrow Failure, EBMT Handbook 2024

What PNH flow cytometry contributes

PNH testing identifies populations of cells that lack particular protective surface proteins. These populations can coexist with aplastic anemia and provide both diagnostic context and a baseline for follow-up. The report should identify the cell populations examined, clone measurements, and assay sensitivity. Previous transfusions can affect interpretation of some findings.

A small detected clone usually leads to clinical correlation rather than an automatic prescription for a PNH medicine. The clinician may assess lactate dehydrogenase, bilirubin, urine changes, abdominal symptoms, and thrombosis clues to determine whether hemolysis or another PNH manifestation is important. When inadequate marrow production remains the principal problem, the treatment focus remains aplastic anemia. One negative test does not guarantee that later reassessment will never be relevant. The 2026 ASH recommendations include PNH evaluation in the appropriate severe and refractory settings. ASH 2026 aplastic anemia guidelines

When inherited marrow failure needs investigation

Childhood onset, relatives with similar disease, congenital differences, early cancers, or unexplained pulmonary fibrosis and liver disease can prompt inherited-disease assessment. Absence of these clues does not completely exclude an inherited disorder. The question becomes especially important before transplantation because an unrecognized condition can change conditioning tolerance or make an apparently healthy relative unsuitable as a donor.

Telomere-length measurement, chromosome-breakage testing, and germline sequencing serve different purposes. Telomeres are protective chromosome-end structures, and their measured length needs interpretation against age and method. Fanconi anemia assessment may involve the cellular response to particular forms of damage; neither a routine blood count nor an ordinary chromosome karyotype substitutes for that evaluation. A marrow-failure team should select a coherent testing sequence. Diaz-de-Heredia et al.: Hereditary Bone Marrow Failure Syndromes, EBMT Handbook 2024

Germline testing may require a specimen that represents constitutional genetics rather than only the blood-forming compartment. Whether another tissue is needed and which findings would matter to relatives should be discussed before testing. A variant of uncertain significance should not be used by a family to diagnose one another, while a negative result still has the limits of the assay performed. The Fanconi anemia reference illustrates why clinical, functional, and molecular evidence must be considered together. GeneReviews: Fanconi Anemia, January 2026 update

Turn the results into a usable clinical conclusion

The final assessment should say whether acquired aplastic anemia is supported, what severity applies, which alternatives have been excluded, what remains unresolved, and what support is required while waiting. Severe aplastic anemia is defined through marrow and several blood-cell findings; severe anemia alone is not the same diagnosis. If treatment has already been given, the team should specify the time point used for classification.

A failed chromosome culture remains an uninformative result rather than a normal karyotype. Subsequent results also need methodological comparison: a broader sequencing panel may reveal something that an earlier assay never measured. Long-term follow-up can identify clonal changes that warrant another marrow examination, but that examination is answering a new clinical question rather than proving the initial workup had no value. Patel et al.: Long-term outcomes after immunosuppression and eltrombopag

For a potential transplant candidate, HLA typing can begin while final diagnostic details are being resolved. This reduces avoidable later delay without committing the patient to transplantation. Donor assessment and the patient’s diagnosis are connected, particularly if an inherited disorder remains possible. A related donor should not be cleared by a compatibility result alone when the family’s underlying condition has not been explained.

Arrange a second opinion and a realistic testing budget

For a diagnostic review in China, send serial counts, reticulocytes, complete aspirate and biopsy reports, original karyotype wording, PNH findings, and a medication/transfusion timeline. Ask whether slides, blocks, or other original material are required and how the hospital receives them. Translation should preserve units, specimen type, and qualifiers such as uncertain or unable to analyze. A phone image containing only the conclusion page is often insufficient.

Separate appointment availability, pathology review, repeat sampling, and external genetic studies when asking about timing. There is no fixed number of days applicable to every workup. The hospital should identify which findings can be reported first and which could affect the start of treatment. Local arrangements for transfusion and infection management must continue while the outside review proceeds.

Request renminbi quotations for consultation, slide review, additional staining, marrow sampling, flow cytometry, chromosome work, and molecular or functional testing as distinct items. State the international self-pay category and clarify whether consumables, pathology, and outside laboratory charges are included. No verified individualized total is available here, so a broad unsupported price range is not supplied. Before paying for a repeated investigation, ask whether the original report or specimen is adequate for the clinical question now being considered.